← Back to headlines
Harvard Bioscience Outlines 2026 Guidance with Revenue Growth and High-Margin Focus
Harvard Bioscience has provided its 2026 guidance, projecting 2%–4% revenue growth and a focus on high-margin products following recent structural improvements.
12 Mar, 14:03 — 12 Mar, 14:03
Sources
Showing 1 of 1 sources
